Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity

AC Mares, S Chatterjee… - Current Opinion in …, 2022 - journals.lww.com
Semaglutide for weight loss and cardiometabolic risk reducti... : Current Opinion in Cardiology
Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity : Current …
被引用次数：7 相关文章

Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity

AC Mares, S Chatterjee… - Current opinion in …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose of review Cardiovascular disease is the most common cause of morbidity and
mortality worldwide, and the risk is heightened in the presence of obesity. We review …

Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity

AC Mares, S Chatterjee… - Current Opinion in …, 2022 - ingentaconnect.com
Purpose of review Cardiovascular disease is the most common cause of morbidity and
mortality worldwide, and the risk is heightened in the presence of obesity. We review …

Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.

AC Mares, S Chatterjee, D Mukherjee - Current Opinion in …, 2022 - europepmc.org
Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu …